Metformina Eg Stada Group

Metformin, the active ingredient in Metformina Eg Stada Group, is a biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels.

GNH USA supplies Metformina Eg Stada Group as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Our distribution network ensures timely delivery and reliable product integrity across diverse markets.

Metformina Eg Stada Group (metformin) is used in the management of glucose metabolism disorders, primarily type 2 diabetes.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose. - Prediabetes (impaired glucose tolerance): reduces the risk of progression to type 2 diabetes. - Polycystic ovary syndrome (off‑label): enhances insulin sensitivity and may help regulate menstrual cycles.

Metformina Eg Stada Group may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Vitamin B12 deficiency: gradual decrease with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe hypoglycemia: when combined with other glucose‑lowering agents. - Hepatic dysfunction: signs of liver injury. - Skin rash or hypersensitivity: including Stevens‑Johnson syndrome. - Persistent gastrointestinal bleeding: rare but serious.

When prescribing Metformina Eg Stada Group, clinicians should consider several safety aspects.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: avoid use in patients with severe liver disease. - Lactic acidosis risk: discontinue if patient develops unexplained fatigue, dyspnea, or abdominal pain. - Vitamin B12 monitoring: check levels during long‑term therapy. - Alcohol consumption: advise patients to limit intake to reduce lactic acidosis risk. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metformina Eg Stada Group can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycemia; monitor blood glucose. - ACE inhibitors or ARBs: may affect renal function; observe renal parameters. - Diuretics: can reduce renal clearance of metformin; adjust dose if needed.